Home > Insider Trading > Filing (0001689813-19-000095)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1226675	P Julia Gregory	C/O Biohaven Pharmaceuticals, Inc., 215 Church Street New Haven CT 06510		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2019-11-22	12,000	$23.63	12,000	No	4	M	Direct
Common Shares	Disposition	2019-11-22	12,000	$54.75	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2019-11-22	12,000	$0.00	12,000	$23.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,000		2027-08-01	No	4	M	Direct

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.01 - $55.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
This option grant was made pursuant to the Issuer's non-employee director compensation policy. The option, representing a right to purchase a total of 36,000 shares was granted on August 2, 2017, vesting in three equal installments on August 2, 2018, 2019 and 2020, subject to the Reporting Person's continuous service with the Issuer at each vesting date. The Reporting Person previously exercised the option with respect to 12,000 shares on February 21, 2019.